|
May 22
|
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
|
|
May 22
|
Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three years
|
|
May 21
|
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
|
|
May 6
|
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
|
|
May 2
|
Oppenheimer Predicts Over 100% Rally for These 2 Healthcare Stocks
|
|
Apr 10
|
Insider Spends US$67k Buying More Shares In AngioDynamics
|
|
Apr 8
|
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript
|
|
Apr 6
|
AngioDynamics Third Quarter 2024 Earnings: Misses Expectations
|
|
Apr 5
|
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
|
|
Apr 5
|
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
|
|
Apr 5
|
Q3 2024 AngioDynamics Inc Earnings Call
|
|
Apr 4
|
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
|
|
Apr 4
|
AngioDynamics Inc (ANGO) Posts Q3 Fiscal 2024 Results: A Mixed Performance Amidst Asset Divestiture
|
|
Apr 4
|
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
|
|
Apr 4
|
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
|
|
Apr 2
|
AngioDynamics (ANGO) Settles Patent Litigations With BD
|
|
Apr 1
|
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
|
|
Mar 19
|
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
|
|
Mar 15
|
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
|
|
Mar 8
|
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
|